Money
Filter News
Found 84,828 articles
-
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 05, 2024
4/5/2024
Inozyme Pharma, Inc. announced that it granted stock options to three new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.
-
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 05, 2024
4/5/2024
ORIC Pharmaceuticals, Inc. announced that on April 1, 2024, ORIC granted a total of 84,800 non-qualified stock options and 14,400 restricted stock units to two new non-executive employees who began their employment with ORIC in March 2024.
-
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 05, 2024
4/5/2024
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, announced that it granted equity awards on April 1, 2024, to six newly-hired, non-executive employees.
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - April 05, 2024
4/5/2024
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to two new employees.
-
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 05, 2024
4/5/2024
Atara Biotherapeutics, Inc. reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee.
-
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 05, 2024
4/5/2024
Syndax Pharmaceuticals announced that on April 1, 2024 the Company granted inducement awards to purchase up to 164,200 shares of common stock to ten new employees under the Company's 2023 Inducement Plan.
-
Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today
4/5/2024
Eupraxia Pharmaceuticals Inc. announced that trading of the Company's common shares will begin today, April 5, 2024, on the Nasdaq Capital Market, under the ticker symbol "EPRX".
-
NeuBase Therapeutics Announces Receipt of Notice from Nasdaq - April 05, 2024
4/5/2024
NeuBase Therapeutics, Inc. reported that it received a notice on April 4, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250 as a result of its failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 in a timely manner.
-
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 05, 2024
4/5/2024
89bio, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 138,550 shares of the Company’s common stock to eight new employees on April 3, 2024.
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 05, 2024
4/5/2024
Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 58,500 restricted stock units of Arcutis’ common stock to four newly hired employees.
-
Nutex Health Announces 1-for-15 Reverse Stock Split
4/5/2024
Nutex Health Inc., announced a 1-for-15 reverse stock split of its common stock effective with the market opening on Tuesday April 10, 2024.
-
Contineum Therapeutics Announces Pricing of Initial Public Offering - April 05, 2024
4/5/2024
Contineum Therapeutics, Inc. announced the pricing of its initial public offering of 6,875,000 shares of its Class A common stock at a price to the public of $16.00 per share.
-
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 05, 2024
4/5/2024
IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that, on March 28, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 70,000 shares of the Company's common stock to two newly hired employees.
-
Aquaporin announces full-year 2023 results, with year-on-year revenue growth of 95%
4/5/2024
Aquaporin A/S announced the Annual Report for the period January 1 to December 31, 2023.
-
Leash Biosciences Announces $9.3 Million Seed Financing to Pioneer AI-Driven Medicinal Chemistry
4/5/2024
Leash Biosciences today announced the completion of a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection.
-
Amid a flurry of deals in the antibody-drug conjugate space, Merck KGaA is getting in on the action with a partnership with Caris Life Sciences to accelerate the discovery and development of first-in-class ADCs for oncology.
-
Three Biopharma firms disclosed concerns about how emerging geopolitical tensions between the U.S. and China might impact their business with the contract manufacturer.
-
The American Association for Cancer Research has invited drug developers and investors to intermingle with the academics who typically attend its annual conference.
-
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
4/4/2024
BiomX Inc. announced that, as previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the Securities and Exchange Commission on April 4, 2024, the audit opinion contained a going concern qualification from the Company's independent registered public accounting firm.
-
Extendicare Announces Timing of 2024 First Quarter Results and Conference Call
4/4/2024
Extendicare Inc. announced that it plans to release its financial results for the first quarter of 2024 after market close on Wednesday, May 15, 2024.